Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’s Luxturna Deal Expands Gene Therapy Ambitions

Executive Summary

By licensing Spark Therapeutics' Luxturna outside the US, Novartis is expanding its gene therapy ambitions into in vivo and non-oncological treatments.

Advertisement

Related Content

Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies
Eight Things To Know From Novartis' Third Quarter Call
Novartis Sees The Light And Plumps For Alcon Spin-Off
Novartis Sees The Light And Plumps For Alcon Spin-Off
Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition
Novartis’s Chief Medical Officer On All Things MS And The Science Of Operations
Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy
Spark's Luxturna Approval Ushers In A New Gene Therapy Era
What's Gilead Getting From Kite For Nearly $12bn?
Novartis/Penn To Research Chimeric Antigen Receptor Immunotherapies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100269

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel